Report
EUR 12.84 For Business Accounts Only

HENAN LINGRUI PHARM. sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of HENAN LINGRUI PHARM. (CN), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date February 14, 2020, the closing price was CNY 9.45 and its target price was estimated at CNY 8.44.
Underlying
Henan Lingrui Pharmaceutial (A)

Henan Lingrui Pharmaceutical and its subsidiaries are engaged in the manufacture and distribution of medicines, health care products and medical equipment; research and development of new products and new technology; provision of technical services; export of self-produced products and related technologies; import of raw materials, materials for experiment, machinery and equipment, instruments and meters, spare parts and other related technologies; provision of information services; and investment in real estate, cultural education, advertising and hotel.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener